TROG 04.01 - Cavilon Breast - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Clinical Trial Registration

Registration Link

David, Jasmine and Susan Goode, re Kokoda Challenge to support TROG Cancer Research

27 May, 2025

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work

LATEST NEWS: 27 MAY 2025 TROG members and staff

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

TROG 01.02 – PCNSL

NCIC CTG SC.20/TROG 03.08/BONEMETS

Related Post

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work

TROG 04.01 – Cavilon Breast

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

TROG 01.02 – PCNSL

NCIC CTG SC.20/TROG 03.08/BONEMETS

Related Post

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work